Skip to main content
2022 Guide to Patient Support Services

Lilly Oncology

2022 Oncology Guide to Patient Support Services

Lilly Oncology Support Center

866-472-8663

Eli Lilly and Company, through Lilly Oncology, offers financial assistance to qualified patients who are prescribed oncology medications and who need help paying for their medications. The complete list of Lilly Oncology drugs and their patient support programs is provided in the Table.

Lilly Oncology Support Center

The Lilly Oncology Support Center provides services to patients and providers, including assistance with infused products, the Retevmo Support Program, the Verzenio Continuous Care support program, and the Lilly Cares Foundation.

Infused Products Enrollment Form

By enrolling in the Lilly Oncology Support Center, patients may receive various forms of support and information to help access infused oncology products, including benefits investigation support, financial support, and ongoing support. To enroll your patient, complete the application and fax to 877-366-0585.

Retevmo Support Program

This program provides ongoing support services for patients who have been prescribed Retevmo, including benefits investigation support, the MyRightDose Program, the Retevmo Interim Access Program support, and other support services. To enroll your patient, complete the application and fax to 877-427-4030.

The Retevmo MyRightDose Program allows patients who are prescribed Retevmo to continue therapy with Retevmo at the appropriate dose, without delays or costs to the patient. Retevmo can be shipped to the patients as early as 48 hours after enrollment in the MyRightDose Program. To be eligible for the program, patients must:

  • Return unused pills in the preaddressed envelope, according to the instructions provided
  • Be aged ≥18 years (>12 years for patients with thyroid cancer)
  • Be a resident of the United States or Puerto Rico
  • Have a prescription for Retevmo for an FDA-approved indication.

The application for the Retevmo MyRightDose Program is available online. The completed form should be faxed to 844-372-9043. Click here for more information on the MyRightDose Program for Retevmo, or call 833-290-2175.

Verzenio Continuous Care Program

This program provides ongoing support services for patients who have been prescribed Verzenio, including benefits investigation support, the MyRightDose Program, the Companion in Care Program, and other support services. To be eligible for the Verzenio Continuous Care Program, patients must be aged ≥18 years, have been prescribed Verzenio for an FDA-approved indication, and meet the eligibility requirements. To enroll your patient, complete the application and fax to 855-545-5957.

The Verzenio MyRightDose Program allows patients who are prescribed Verzenio to continue therapy with Verzenio at the appropriate dose, without delays or costs to the patient. Verzenio can be shipped to the patients as early as 48 hours after enrollment in the MyRightDose Program. To be eligible for the program, patients must:

  • Return unused pills in the preaddressed envelope, according to the instructions provided
  • Be aged ≥18 years
  • Be a resident of the United States or Puerto Rico
  • Have a prescription for Verzenio for an FDA-approved indication.

The application for the Verzenio MyRightDose Program is available online. The completed form should be faxed to 833-665-6329. Click here for more information on the MyRightDose Program for Verzenio, or call 833-557-2417.

Once enrolled in the Verzenio Continuous Care Program, patients have access to the Companion in Care Program. This program provides patients with help from the same person every time to clarify treatment expectations, provide emotional support, answer questions about side effects, and guide patients back to your practice for medical advice.

Lilly Cares Foundation

The Lilly Cares Foundation provides the Patient Assistance Program for uninsured or underinsured patients who have been prescribed Lilly Oncology medications. Patients may be eligible for this program if they:

  • Are permanent, legal residents of the United States, Puerto Rico, or the US Virgin Islands
  • Have been prescribed a qualifying Lilly medication
  • Have no insurance, or have Medicare Part D
  • Are not enrolled in or have been denied Medicaid, full Low Income Subsidy (LIS, “Extra Help”) or Veterans (VA) Benefits (Humatrope patients with VA and Medicaid benefits may be eligible. Humatrope patients: call Lilly Cares to review eligibility requirements)
  • You meet the household income guidelines for the program.

For more information, please visit LillyCares.com.

TABLE Lilly Oncology Drugs

Drugs
Indications
Patient support programs

Drug
Alimta (pemetrexed) for injection
Indications
Patient support programs



Drug
Portrazza (necitumumab) injection
Indications
Metastatic squamous NSCLC, in combination with gemcitabine and cisplatin
Patient support programs

Drug
Retevmo (selpercatinib) capsules
Indications
Treatment of adults with metastatic RET fusion–positive NSCLC; treatment of patients aged ≥12 years with advanced or metastatic medullary thyroid cancer and RET mutation who require systemic therapy; treatment of patients aged ≥12 years with advanced or metastatic RET fusion–positive thyroid cancer who require systemic therapy and who are radioactive iodine–refractory (if radioactive iodine is appropriate)
Patient support programs

Drug
Verzenio (abemaciclib) tablets
Indications
Patient support programs

HR indicates hormone receptor; NSCLC, non–small-cell lung cancer.

Alimta (pemetrexed) for injection Indications

Initial treatment in combination with pembrolizumab and platinum chemotherapy for nonsquamous metastatic NSCLC with no EGFR or ALK genomic tumor aberrations; initial treatment in combination with cisplatin for locally advanced or metastatic nonsquamous NSCLC; single agent in recurrent metastatic nonsquamous NSCLC after prior chemotherapy; single agent as maintenance therapy in patients with locally advanced or metastatic nonsquamous NSCLC whose disease has not progressed after 4 cycles of platinum-based first-line chemotherapy; in combination with cisplatin, for the initial treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery

Cyramza (ramucirumab) Indications

Metastatic gastric cancer, as monotherapy, or in combination with paclitaxel; metastatic NSCLC, in combination with docetaxel; metastatic colorectal cancer, in combination with irinotecan, folinic acid, and 5-fluorouracil; as monotherapy of hepatocellular carcinoma in patients with alpha-fetoprotein of ≥400 mg/mL, after sorafenib therapy; first-line treatment, in combination with erlotinib, of metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations

Erbitux (cetuximab) Indications

Initial treatment of locally or regionally advanced squamous-cell carcinoma of the head and neck (SCCHN), in combination with radiation; first-line treatment of patients with recurrent locoregional disease or metastatic SCCHN, in combination with platinum-based therapy; treatment of recurrent or metastatic SCCHN after failing platinum-based therapy; treatment of metastatic colorectal cancer that is EGFR-expressing, KRAS wild-type, as determined by an FDA-approved test, as first-line treatment, in combination with irinotecan, fluorouracil, and leucovorin, or in combination with irinotecan, in disease refractory to irinotecan-based chemotherapy or progressing after oxaliplatin- and irinotecan-based chemotherapy or intolerant to irinotecan

Verzenio (abemaciclib) tablets Indications

As initial endocrine-based therapy, in combination with an aromatase inhibitor, for postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer; treatment of HR-positive, HER2-negative advanced or metastatic breast cancer, in combination with fulvestrant, for disease that progressed after endocrine therapy; treatment of HR-positive, HER2-negative advanced or metastatic breast cancer, as monotherapy, for disease that progressed after endocrine therapy and previous chemotherapy in the metastatic setting

Report Broken Links

Have you encountered a problem with a URL (link) on this page not loading correctly or is displaying an error message?

Help us fix it! Report broken links here.

Report Broken Links

Report Broken Links

*OPM Webpage
Please copy the URL (link) of the OPM webpage you are currently on.
*Broken Link
Please copy the URL (link) to the external webpage that is not displaying content correctly.
Errors include, but are not limited to:
  • "This site can’t be reached"
  • "Hmm. We’re having trouble finding that site."
  • "Hmmm… can't reach this page"
  • "404 Error: Page not found"
Comments
(Optional)